Printer Friendly

TKT Appoints Theresa Heggie as General Manager, Europe.

CAMBRIDGE, Massachusetts, February 4 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) announced today the appointment of Theresa Heggie, formerly Vice President Global Marketing for the Anesthesia and Critical Care business unit of Baxter Healthcare, to the new position of General Manager, TKT Europe.

"Theresa has a proven commercial and European track record and we are delighted to welcome her to our organization. Her experience will be valuable to us as she assumes leadership of the TKT team that launched Replagal in Europe, and then achieved consistent sales growth over the past three years. They have marketed Replagal with an emphasis on the science and innovative services for physicians and patients and established an important platform in Europe for our new product launches. As we look to introduce additional lysosomal storage disease products into the franchise, we intend to build on this strong foundation," said Dr. David Pendergast, Chief Operating Officer of TKT.

Ms. Heggie joins TKT Europe with over 20 years of healthcare experience both in the United States and overseas. Early in her career she held sales representative positions at Dow Chemical and Janssen Pharmaceutical before assuming a variety of marketing positions of increasing responsibility at Ohmeda Pharmaceutical Products Division (PPD) from 1991 to 1998. At Ohmeda, Ms. Heggie directed the U.S. launch of Suprane, an inhaled anesthetic and the pre-marketing plan for inhaled nitric oxide for the treatment of persistent pulmonary hypertension in newborns. Following the 1998 acquisition of Ohmeda PPD by Baxter, Ms. Heggie was named Vice President Anesthesia and Critical Care, Europe, a business unit of Baxter's Medication Delivery Division, where she had responsibility for marketing, sales, medical and regulatory affairs, finance and logistics. At the end of her thirteen-year tenure at Baxter (Ohmeda), Ms. Heggie held the position Vice President, Global Marketing of the Anesthesia and Critical Care business unit and was responsible for the establishment and management of their global marketing function, including strategic planning and life cycle management for several key products. Ms. Heggie, aged 44, received a B.Sc. from Cornell University.

About TKT

Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at

This press release contains forward-looking statements regarding TKT's management structure, as well as statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including, whether TKT will be able to successfully manage its European operations; ability to launch new products in Europe and other factors set forth under the caption "Certain Factors Which May Affect Future Results" in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004, which is on file with the Securities and Exchange Commission and are incorporated herein by reference. While the company may elect to update forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its expectations change.

Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Avenits. Suprane(R) is a registered trademark of Baxter.

 For More Information Contact:
 Justine E. Koenigsberg
 Senior Director, Corporate Communications

 Daniella M. Lutz
 Corporate Communications Manager

Web site:

Justine E. Koenigsberg, Senior Director, Corporate Communications, +1-617-349-0271; or Daniella M. Lutz, Corporate Communications Manager, +1-617-349-0205 both of Transkaryotic Therapies, Inc. ; Photo: NewsCom: ; AP Archive: ; PRN Photo Desk, ; Company News On-Call:
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Feb 4, 2005
Previous Article:Nissan Europe Reports January Sales.
Next Article:Custom House Salutes Rugby Canada Players Awarded for Athletic Excellence.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters